8/15/2011 Savara Receives Grant Award from National Institute of Allergy and Infectious Diseases
Proceeds used to progress Pediatric Asthma Therapeutic to IND

Austin, TX, Aug. 15, 2011 -- Savara Inc., an inhalation product development company, was recently awarded a Phase I grant from the National Institute of Allergy and Infectious Diseases (NIAID).

After NIAID and independent review, reviewers concluded that Savara’s proposed therapeutic addresses an important clinical need in pediatric asthma. With innovative foundational technology, a clear clinical path and a team with a proven track record of product development, NIAID selected to fund Savara from a large pool of applicants. This provides additional validation of the program’s clinical potential and progress to date.

“These additional funds have come at a critical time in this product’s development,” said Rob Neville, CEO of Savara. “We will use these funds to produce clinical supply in support of our upcoming trials.”

Savara anticipates filling a Phase II application later this year upon completion of the Phase I milestones. Phase II funding has the potential for a significant increase in funding support upon successful review.

About Savara Inc.

Savara Inc. (www.savarapharma.com) is an inhalation drug development company targeting niche therapeutic areas with high unmet medical need and high commercial opportunity. Savara focuses on improving existing small molecule medicines through advanced formulation and delivery technologies across a number of therapeutic areas including asthma, cystic fibrosis and lung cancer.